Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines
Purpose Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we eva...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2023-10, Vol.149 (13), p.10975-10987 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10987 |
|---|---|
| container_issue | 13 |
| container_start_page | 10975 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 149 |
| creator | Milosevic, Emilija Stanisavljevic, Nemanja Boskovic, Srdjan Stamenkovic, Nemanja Novkovic, Mirjana Bavelloni, Alberto Cenni, Vittoria Kojic, Snezana Jasnic, Jovana |
| description | Purpose
Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
Methods
The toxicity of violacein was assessed in vitro and in vivo, using MTT assay and FET test. The effect of violacein on cell migration was monitored by wound healing assay, cell death by flow cytometry, uptake of violacein by fluorescence microscopy, generation of reactive oxygen species (ROS) by DCFH-DA assay and lipid peroxidation by TBARS assay.
Results
Violacein IC
50
values for OS and RMS cells were in a range from 0.35 to 0.88 µM. Its selectivity toward malignant phenotype was confirmed on non-cancer V79-4 cells, and it was safe in vivo, for zebrafish embryos in doses up to 1 µM. Violacein induced apoptosis and affected the migratory potential of OS and RMS cells. It was found on the surfaces of tested cells. Regarding the mechanism of action, violacein acted on OS and RMS cells independently of oxidative signaling, as judged by no increase in intracellular ROS generation and no lipid peroxidation.
Conclusion
Our study provided further evidence that reinforces the potential of violacein as an anticancer agent and candidate to consider for improvement of the effectiveness of traditional OS and RMS therapies. |
| doi_str_mv | 10.1007/s00432-023-04930-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2822367849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2822367849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-54f495914f5ec6bae8ce12f235e0b8522d59c26c20ae498e8ee48677f77c015d3</originalsourceid><addsrcrecordid>eNp9kU9PGzEQxS1EBSHtF-ihssSllwX_Xe8eo4gCUiQu9Gw53tnUaNcOtjdSvj0OASpx4DTy-DdvRu8h9JOSK0qIuk6ECM4qwnhFRMtJ1Z6gGT20KOfyFM0IVbSSjNbn6CKlJ1LeUrEzdM4VU0RxMUPdwmeXpzFEbGx2O5f3OPTYmzxFM-Ct24zgM965MBgLzmOzMc6njEPKEJKJNowGG9_h-M-suzDuP5oWhgEPzkP6jr71Zkjw463O0d8_N4_Lu2r1cHu_XKwqK2ibKyl60cqWil6CrdcGGguU9YxLIOtGMtbJ1rLaMmJAtA00AKKpleqVsoTKjs_R76PuNobnCVLWo0uHM4yHMCXNGsZ4rZpi1hxdfkKfwhR9ua5QspHFq5oVih0pG0NKEXq9jW40ca8p0YcM9DEDXTLQrxnog_SvN-lpPUL3MfJuegH4EUjly28g_t_9hewL1yOSqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858500162</pqid></control><display><type>article</type><title>Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines</title><source>SpringerLink Journals - AutoHoldings</source><creator>Milosevic, Emilija ; Stanisavljevic, Nemanja ; Boskovic, Srdjan ; Stamenkovic, Nemanja ; Novkovic, Mirjana ; Bavelloni, Alberto ; Cenni, Vittoria ; Kojic, Snezana ; Jasnic, Jovana</creator><creatorcontrib>Milosevic, Emilija ; Stanisavljevic, Nemanja ; Boskovic, Srdjan ; Stamenkovic, Nemanja ; Novkovic, Mirjana ; Bavelloni, Alberto ; Cenni, Vittoria ; Kojic, Snezana ; Jasnic, Jovana</creatorcontrib><description>Purpose
Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
Methods
The toxicity of violacein was assessed in vitro and in vivo, using MTT assay and FET test. The effect of violacein on cell migration was monitored by wound healing assay, cell death by flow cytometry, uptake of violacein by fluorescence microscopy, generation of reactive oxygen species (ROS) by DCFH-DA assay and lipid peroxidation by TBARS assay.
Results
Violacein IC
50
values for OS and RMS cells were in a range from 0.35 to 0.88 µM. Its selectivity toward malignant phenotype was confirmed on non-cancer V79-4 cells, and it was safe in vivo, for zebrafish embryos in doses up to 1 µM. Violacein induced apoptosis and affected the migratory potential of OS and RMS cells. It was found on the surfaces of tested cells. Regarding the mechanism of action, violacein acted on OS and RMS cells independently of oxidative signaling, as judged by no increase in intracellular ROS generation and no lipid peroxidation.
Conclusion
Our study provided further evidence that reinforces the potential of violacein as an anticancer agent and candidate to consider for improvement of the effectiveness of traditional OS and RMS therapies.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-023-04930-9</identifier><identifier>PMID: 37270734</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antitumor activity ; Antitumor agents ; Apoptosis ; Bone cancer ; Bone tumors ; Cancer Research ; Cell death ; Cell migration ; Connective tissues ; Embryos ; Flow cytometry ; Fluorescence microscopy ; Hematology ; Internal Medicine ; Intracellular signalling ; Lipid peroxidation ; Medicine ; Medicine & Public Health ; Natural products ; Oncology ; Osteosarcoma ; Pediatrics ; Phenotypes ; Reactive oxygen species ; Rhabdomyosarcoma ; Sarcoma ; Toxicity ; Tumor cells ; Violacein ; Wound healing</subject><ispartof>Journal of cancer research and clinical oncology, 2023-10, Vol.149 (13), p.10975-10987</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-54f495914f5ec6bae8ce12f235e0b8522d59c26c20ae498e8ee48677f77c015d3</citedby><cites>FETCH-LOGICAL-c419t-54f495914f5ec6bae8ce12f235e0b8522d59c26c20ae498e8ee48677f77c015d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-023-04930-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-023-04930-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37270734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Milosevic, Emilija</creatorcontrib><creatorcontrib>Stanisavljevic, Nemanja</creatorcontrib><creatorcontrib>Boskovic, Srdjan</creatorcontrib><creatorcontrib>Stamenkovic, Nemanja</creatorcontrib><creatorcontrib>Novkovic, Mirjana</creatorcontrib><creatorcontrib>Bavelloni, Alberto</creatorcontrib><creatorcontrib>Cenni, Vittoria</creatorcontrib><creatorcontrib>Kojic, Snezana</creatorcontrib><creatorcontrib>Jasnic, Jovana</creatorcontrib><title>Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
Methods
The toxicity of violacein was assessed in vitro and in vivo, using MTT assay and FET test. The effect of violacein on cell migration was monitored by wound healing assay, cell death by flow cytometry, uptake of violacein by fluorescence microscopy, generation of reactive oxygen species (ROS) by DCFH-DA assay and lipid peroxidation by TBARS assay.
Results
Violacein IC
50
values for OS and RMS cells were in a range from 0.35 to 0.88 µM. Its selectivity toward malignant phenotype was confirmed on non-cancer V79-4 cells, and it was safe in vivo, for zebrafish embryos in doses up to 1 µM. Violacein induced apoptosis and affected the migratory potential of OS and RMS cells. It was found on the surfaces of tested cells. Regarding the mechanism of action, violacein acted on OS and RMS cells independently of oxidative signaling, as judged by no increase in intracellular ROS generation and no lipid peroxidation.
Conclusion
Our study provided further evidence that reinforces the potential of violacein as an anticancer agent and candidate to consider for improvement of the effectiveness of traditional OS and RMS therapies.</description><subject>Antitumor activity</subject><subject>Antitumor agents</subject><subject>Apoptosis</subject><subject>Bone cancer</subject><subject>Bone tumors</subject><subject>Cancer Research</subject><subject>Cell death</subject><subject>Cell migration</subject><subject>Connective tissues</subject><subject>Embryos</subject><subject>Flow cytometry</subject><subject>Fluorescence microscopy</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Intracellular signalling</subject><subject>Lipid peroxidation</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Natural products</subject><subject>Oncology</subject><subject>Osteosarcoma</subject><subject>Pediatrics</subject><subject>Phenotypes</subject><subject>Reactive oxygen species</subject><subject>Rhabdomyosarcoma</subject><subject>Sarcoma</subject><subject>Toxicity</subject><subject>Tumor cells</subject><subject>Violacein</subject><subject>Wound healing</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU9PGzEQxS1EBSHtF-ihssSllwX_Xe8eo4gCUiQu9Gw53tnUaNcOtjdSvj0OASpx4DTy-DdvRu8h9JOSK0qIuk6ECM4qwnhFRMtJ1Z6gGT20KOfyFM0IVbSSjNbn6CKlJ1LeUrEzdM4VU0RxMUPdwmeXpzFEbGx2O5f3OPTYmzxFM-Ct24zgM965MBgLzmOzMc6njEPKEJKJNowGG9_h-M-suzDuP5oWhgEPzkP6jr71Zkjw463O0d8_N4_Lu2r1cHu_XKwqK2ibKyl60cqWil6CrdcGGguU9YxLIOtGMtbJ1rLaMmJAtA00AKKpleqVsoTKjs_R76PuNobnCVLWo0uHM4yHMCXNGsZ4rZpi1hxdfkKfwhR9ua5QspHFq5oVih0pG0NKEXq9jW40ca8p0YcM9DEDXTLQrxnog_SvN-lpPUL3MfJuegH4EUjly28g_t_9hewL1yOSqw</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Milosevic, Emilija</creator><creator>Stanisavljevic, Nemanja</creator><creator>Boskovic, Srdjan</creator><creator>Stamenkovic, Nemanja</creator><creator>Novkovic, Mirjana</creator><creator>Bavelloni, Alberto</creator><creator>Cenni, Vittoria</creator><creator>Kojic, Snezana</creator><creator>Jasnic, Jovana</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines</title><author>Milosevic, Emilija ; Stanisavljevic, Nemanja ; Boskovic, Srdjan ; Stamenkovic, Nemanja ; Novkovic, Mirjana ; Bavelloni, Alberto ; Cenni, Vittoria ; Kojic, Snezana ; Jasnic, Jovana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-54f495914f5ec6bae8ce12f235e0b8522d59c26c20ae498e8ee48677f77c015d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antitumor activity</topic><topic>Antitumor agents</topic><topic>Apoptosis</topic><topic>Bone cancer</topic><topic>Bone tumors</topic><topic>Cancer Research</topic><topic>Cell death</topic><topic>Cell migration</topic><topic>Connective tissues</topic><topic>Embryos</topic><topic>Flow cytometry</topic><topic>Fluorescence microscopy</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Intracellular signalling</topic><topic>Lipid peroxidation</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Natural products</topic><topic>Oncology</topic><topic>Osteosarcoma</topic><topic>Pediatrics</topic><topic>Phenotypes</topic><topic>Reactive oxygen species</topic><topic>Rhabdomyosarcoma</topic><topic>Sarcoma</topic><topic>Toxicity</topic><topic>Tumor cells</topic><topic>Violacein</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Milosevic, Emilija</creatorcontrib><creatorcontrib>Stanisavljevic, Nemanja</creatorcontrib><creatorcontrib>Boskovic, Srdjan</creatorcontrib><creatorcontrib>Stamenkovic, Nemanja</creatorcontrib><creatorcontrib>Novkovic, Mirjana</creatorcontrib><creatorcontrib>Bavelloni, Alberto</creatorcontrib><creatorcontrib>Cenni, Vittoria</creatorcontrib><creatorcontrib>Kojic, Snezana</creatorcontrib><creatorcontrib>Jasnic, Jovana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Milosevic, Emilija</au><au>Stanisavljevic, Nemanja</au><au>Boskovic, Srdjan</au><au>Stamenkovic, Nemanja</au><au>Novkovic, Mirjana</au><au>Bavelloni, Alberto</au><au>Cenni, Vittoria</au><au>Kojic, Snezana</au><au>Jasnic, Jovana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>149</volume><issue>13</issue><spage>10975</spage><epage>10987</epage><pages>10975-10987</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
Methods
The toxicity of violacein was assessed in vitro and in vivo, using MTT assay and FET test. The effect of violacein on cell migration was monitored by wound healing assay, cell death by flow cytometry, uptake of violacein by fluorescence microscopy, generation of reactive oxygen species (ROS) by DCFH-DA assay and lipid peroxidation by TBARS assay.
Results
Violacein IC
50
values for OS and RMS cells were in a range from 0.35 to 0.88 µM. Its selectivity toward malignant phenotype was confirmed on non-cancer V79-4 cells, and it was safe in vivo, for zebrafish embryos in doses up to 1 µM. Violacein induced apoptosis and affected the migratory potential of OS and RMS cells. It was found on the surfaces of tested cells. Regarding the mechanism of action, violacein acted on OS and RMS cells independently of oxidative signaling, as judged by no increase in intracellular ROS generation and no lipid peroxidation.
Conclusion
Our study provided further evidence that reinforces the potential of violacein as an anticancer agent and candidate to consider for improvement of the effectiveness of traditional OS and RMS therapies.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37270734</pmid><doi>10.1007/s00432-023-04930-9</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2023-10, Vol.149 (13), p.10975-10987 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2822367849 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Antitumor activity Antitumor agents Apoptosis Bone cancer Bone tumors Cancer Research Cell death Cell migration Connective tissues Embryos Flow cytometry Fluorescence microscopy Hematology Internal Medicine Intracellular signalling Lipid peroxidation Medicine Medicine & Public Health Natural products Oncology Osteosarcoma Pediatrics Phenotypes Reactive oxygen species Rhabdomyosarcoma Sarcoma Toxicity Tumor cells Violacein Wound healing |
| title | Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A55%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20activity%20of%20natural%20pigment%20violacein%20against%20osteosarcoma%20and%20rhabdomyosarcoma%20cell%20lines&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Milosevic,%20Emilija&rft.date=2023-10-01&rft.volume=149&rft.issue=13&rft.spage=10975&rft.epage=10987&rft.pages=10975-10987&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-023-04930-9&rft_dat=%3Cproquest_cross%3E2822367849%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2858500162&rft_id=info:pmid/37270734&rfr_iscdi=true |